Genotype Directed Therapy in Murine Mismatch Repair Deficient Tumors

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Kucherlapati, Melanie H ^a,b   Esfahani, Shadi ^c   Habibollahi, Peiman ^c   Wang, Junning ^a,b   Still, Eric R ^a,b   Bronson, Roderick T ^a,d   Mahmood, Umar ^c   Kucherlapati, Raju S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ADZ 4266; CYCLIN D1; FLUORODEOXYGLUCOSE F 18; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; UNCLASSIFIED DRUG; WNT PROTEIN;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENDOSCOPY; ENZYME INHIBITION; ENZYME REGULATION; GENE; GENOTYPE; HUMAN; HUMAN CELL; MISMATCH REPAIR; MOUSE; MSH2 GENE; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMALL INTESTINE TUMOR; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA MISMATCH REPAIR; GENE REARRANGEMENT; GENOTYPE; HUMANS; IMIDAZOLES; INTEGRASES; INTESTINAL NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MUTS HOMOLOG 2 PROTEIN; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; TOR SERINE-THREONINE KINASES; UP-REGULATION; WNT PROTEINS;

EID: 84880736747     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068817     Document Type: Article

References (35)

1. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, et al. (2013) Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105: 175-201.
2. National Comprehensive Cancer Network, (2012).
3. Yuan TL, Cantley LC, (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
4. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
5. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
6. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW, (2009) Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276.
7. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
9. Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, et al. (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10: 90.
10. Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, et al. (2012) Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 12: 86.
11. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
12. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, et al. (2009) Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69: 7644-7652.
13. Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A, (2011) The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res 31: 849-854.
14. Xu CX, Li Y, Yue P, Owonikoko TK, Ramalingam SS, et al. (2011) The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 6: e20899.
15. Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, et al. (2012) Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 7: e31331.
16. Clinical Trials Gov, (2012).
17. Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, et al. (2012) Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res 18: 1051-1062.
18. Madison BB, Dunbar L, Qiao XT, Braunstein K, Braunstein E, et al. (2002) Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277: 33275-33283.
19. Kucherlapati MH, Lee K, Nguyen AA, Clark AB, Hou H Jr, et al. (2010) An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. Gastroenterology 138: 993-1002 e1001.
20. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, et al. (2010) Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 107: 1565-1570.
21. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, et al. (2011) The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 6: e25132.
22. Funovics MA, Alencar H, Montet X, Weissleder R, Mahmood U, (2006) Simultaneous fluorescence imaging of protease expression and vascularity during murine colonoscopy for colonic lesion characterization. Gastrointest Endosc 64: 589-597.
23. Abramoff MD, Magalhaes PJ, Ram SJ, (2004) Image Processing with Image J. Biophotonics International. 11: 36-42.
24. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, et al. (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117: 1399-1408.
25. Lengauer C, Kinzler KW, Vogelstein B, (1997) Genetic instability in colorectal cancers. Nature 386: 623-627.
26. Li D, Hu F, Wang F, Cui B, Dong X, et al. (2013) Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer. PLoS One 8: e51240.
27. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
28. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, et al. (1998) Phosphorylation and activation of p70s6k by PDK1. Science 279: 707-710.
29. Sato S, Fujita N, Tsuruo T, (2004) Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway. J Biol Chem 279: 33759-33767.
30. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32.
31. Lyssiotis CA, Cantley LC, (2012) SIRT6 Puts Cancer Metabolism in the Driver's Seat. Cell 151: 1155-1156.
32. Sebastian C, Zwaans BM, Silberman DM, Gymrek M, Goren A, et al. (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151: 1185-1199.
33. Luo J, (2011) Cancer's sweet tooth for serine. Breast Cancer Res 13: 317.
34. DeBerardinis RJ, (2011) Serine metabolism: some tumors take the road less traveled. Cell Metab 14: 285-286.
35. Snell K, Natsumeda Y, Eble JN, Glover JL, Weber G, (1988) Enzymic imbalance in serine metabolism in human colon carcinoma and rat sarcoma. Br J Cancer 57: 87-90.